Daily pill can double survival time for deadliest cancer, trial shows
an hour ago
- #pancreatic cancer
- #breakthrough treatment
- #clinical trial
- A daily pill, daraxonrasib, doubles survival time in patients with advanced pancreatic cancer in a trial.
- The drug targets the Kras protein, which fuels nearly all pancreatic cancers, by inhibiting its activity.
- Patients taking daraxonrasib lived an average of 13.2 months versus 6.6-6.7 months with chemotherapy.
- Experts hail the results as a gamechanger and unprecedented breakthrough in pancreatic cancer treatment.
- The drug is a Ras(On) multi-selective inhibitor, effective regardless of Kras gene variants.
- Future steps include making such drugs widely available and testing them for other cancers like lung and colon.